Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive, multiple congenital anomaly syndrome that was first described by American pediatricians David W. Smith, Luc Lemli, and John M. Opitz in 1964. It is now recognized as one of the most common inborn errors of cholesterol metabolism. The disorder is characterized by a classic triad of microcephaly, distinctive facial features, and syndactyly of the second and third toes, alongside a wide spectrum of visceral, neurological, and growth abnormalities.
The pathophysiology of Smith-Lemli-Opitz syndrome is a paradigm of how a single enzymatic defect in lipid metabolism can produce a multisystem developmental disorder. The syndrome is driven by two synergistic mechanisms: (especially Shh signaling and membrane integrity) and gain of toxic precursor effects (oxidative stress from 7-DHC). Understanding these mechanisms has led directly to therapeutic strategies, including dietary cholesterol supplementation, simvastatin to reduce 7-DHC, and antioxidant therapy. However, since cholesterol does not cross the blood-brain barrier effectively, CNS pathology remains the greatest challenge. Ongoing research focuses on neurosteroid replacement and gene therapy to rescue the cerebral phenotype. For the clinician, recognizing SLOS as a cholesterol biosynthesis disorder is the first step toward accurate diagnosis, genetic counseling, and targeted metabolic management. Note on terminology: The phrase "Fisiopatologia De Smith Thier" likely refers to Smith-Lemli-Opitz syndrome . There is no recognized "Smith-Thier" syndrome; it is almost certainly a phonetic or typographical variant of the correct eponym. Fisiopatologia De Smith Thier
Cholesterol is not merely a structural lipid; it is a critical and a morphogen . Its deficiency explains the majority of the syndromic features. It is now recognized as one of the
At the molecular level, SLOS is caused by pathogenic variants in the DHCR7 gene located on chromosome 11q13.4. This gene encodes the enzyme (also known as 7-dehydrocholesterol reductase). This enzyme catalyzes the final step of cholesterol biosynthesis: the reduction of the double bond at the C7-C8 position of 7-dehydrocholesterol (7-DHC) to produce cholesterol. The syndrome is driven by two synergistic mechanisms: